ISO 10993 Medical Device Sensitization Testing (ISO 10993-10): Methods, Standards, and Regulatory Co

ISO 10993 sensitization testing is a critical component of the biological evaluation of medical devices, designed to determine whether device materials or their extracts can induce delayed-type hypersensitivity reactions in patients. This technical article provides a comprehensive overview of ISO 10993-10 sensitization test requirements, accepted in vivo and in vitro methodologies, sample preparation procedures, and practical guidance for regulatory submissions worldwide.

Technical Overview

Sensitization testing for medical devices is governed by ISO 10993-10, Biological evaluation of medical devices — Part 10: Tests for skin sensitization (current edition ISO 10993-10:2021). The standard addresses the potential of a medical device, or materials extracted from it, to provoke a Type IV delayed hypersensitivity response, clinically manifesting as allergic contact dermatitis after repeated or prolonged exposure. Because sensitization is one of the most frequently reported adverse events associated with skin-contacting and implantable devices, regulatory authorities worldwide treat this endpoint as a fundamental element of biological safety evaluation.

Within the risk-based framework established by ISO 10993-1:2020, the need for sensitization testing is determined by the nature of body contact (surface devices contacting intact skin, mucosal membranes, or breached surfaces; externally communicating devices; and implantable devices) and the cumulative contact duration (limited contact up to 24 hours, prolonged contact from 24 hours to 30 days, and long-term contact exceeding 30 days). Sensitization testing is generally expected for any device with patient contact longer than 24 hours, and for shorter-contact devices when chemical characterization reveals leachable substances of concern.

The 2021 revision of ISO 10993-10 represents a significant evolution, formally acknowledging non-animal test methods aligned with the OECD Test Guideline 442 series and the principles of the 3Rs (replacement, reduction, and refinement of animal use). Laboratories now apply integrated approaches to testing and assessment (IATA), combining in chemico and in vitro data with chemical characterization and existing animal or human evidence, while guinea pig and murine in vivo methods remain fully accepted where justified.

Testing Samples

Polymeric and Plastic Device Materials

Polymers such as PVC, polyurethane, silicone elastomers, polyethylene, and polypropylene constitute the majority of samples submitted for sensitization evaluation. Residual monomers, plasticizers, stabilizers, antioxidants, curing agents, and sterilization by-products may all act as sensitizers, making final-device or representative-material extracts the standard test article.

Metals, Alloys, and Ceramics

Stainless steel, titanium alloys, cobalt-chromium alloys, and nickel-containing materials are evaluated for metal ion release, since nickel, cobalt, and chromium are well-documented contact allergens. Testing is typically performed on device extracts prepared under exaggerated but justified conditions that reflect clinical exposure.

Natural Rubber, Textiles, and Wound Care Products

Natural rubber latex products, accelerators in vulcanized elastomers, textile dyes, and wound dressing components carry historically elevated sensitization risk. These sample types are prioritized for testing regardless of contact duration in many biological evaluation plans.

Coatings, Adhesives, and Combination Products

Hydrophilic coatings, tissue adhesives, drug-eluting components, and inks used for device marking are tested as fully cured, finished formulations. For drug-device and biologic-device combination products, the sensitizing potential of both the device constituent and the active substance must be addressed.

Extracts and Process Samples

Where direct testing of a device is impractical, test laboratories prepare aqueous and non-aqueous extracts according to ISO 10993-12, including process chemicals, residual manufacturing aids, and materials from supplier qualification studies.

Testing Items

ISO 10993-10 and its referenced OECD guidelines support the following sensitization test items, selected based on sample characteristics, regulatory strategy, and animal welfare considerations:

• Guinea Pig Maximization Test (GPMT, Magnusson-Kligman method) — adjuvant-enhanced intradermal and topical induction
• Buehler closed-patch test — non-adjuvant topical induction, suited to devices applied to intact skin
• Murine Local Lymph Node Assay (LLNA, including the radioisotope and BrdU-ELISA variants)
• Direct Peptide Reactivity Assay (DPRA, OECD TG 442C) — in chemico measurement of hapten-like reactivity
• KeratinoSens and LuSens assays (OECD TG 442D) — in vitro keratinocyte Nrf2 pathway activation
• Human Cell Line Activation Test (h-CLAT), U-SENS, and IL-8 Luc assays (OECD TG 442E) — dendritic cell activation markers
• Defined approaches combining multiple non-animal methods per OECD TG 497
• Human repeat insult patch testing and existing clinical evidence, where ethically and scientifically available

Testing Methods

Sample Preparation and Extraction (ISO 10993-12)

Test articles are extracted in both a polar vehicle (such as water, physiological saline, or serum-free culture medium) and a non-polar vehicle (such as sesame oil or another justified oil) to capture hydrophilic and lipophilic leachables. Standardized extraction ratios include 3 cm²/mL for materials thinner than 0.5 mm, 6 cm²/mL for thicker materials, and mass-based ratios of 0.1–0.2 g/mL for irregular solids and elastomers. Common extraction conditions are 37°C for 72 hours, with alternatives of 50°C for 72 hours, 70°C for 24 hours, or 121°C for 1 hour when justified by clinical use and material stability. Extracts used for in vitro assays must be prepared aseptically, and pH and osmolality are controlled to prevent false results.

Guinea Pig Maximization Test (GPMT)

The GPMT is widely regarded as the most sensitive in vivo method and is frequently requested for implantable and prolonged-contact devices. Intradermal induction is performed on day 0 using the test extract together with Freund's Complete Adjuvant, followed by topical induction around day 6. After a rest period, a challenge patch is applied to a naive skin site at approximately day 21, and dermal reactions are graded at 24 and 48 hours after patch removal using a 0-to-3 erythema and edema scale. Responses are compared against vehicle and positive control groups, and positive results are classified by incidence and intensity as weak, mild, moderate, strong, or extreme sensitizers.

Buehler Test

The Buehler method applies the test article under occlusive patches without adjuvant, with induction exposures repeated on days 0, 7, and 14, followed by a challenge at approximately day 28. It is best suited to devices whose clinical exposure is limited to intact skin and to materials where intradermal injection is impractical. Although generally less sensitive than the GPMT, it more closely mimics topical human exposure conditions.

Local Lymph Node Assay (LLNA)

The LLNA measures lymphocyte proliferation in the draining auricular lymph nodes of mice after three consecutive days of ear exposure, with proliferation quantified on day 5 or 6. A stimulation index of 3 or greater indicates sensitization potential. The method reduces animal numbers and avoids the pain associated with elicited dermal reactions, and the BrdU-ELISA variant eliminates radioisotope handling. When applied to medical device extracts, vehicle compatibility and the solubility of leached substances require particular attention.

In Chemico and In Vitro Non-Animal Methods

New approach methodologies address the key mechanistic events of skin sensitization: the DPRA evaluates molecular initiating events by measuring depletion of synthetic cysteine- and lysine-containing peptides; KeratinoSens assesses keratinocyte inflammatory signaling; and h-CLAT and U-SENS evaluate dendritic cell activation via cell surface marker upregulation. Data from these assays can be combined using defined approaches, such as the sequential or two-out-of-three strategies described in OECD TG 497. ISO 10993-10:2021 permits these methods for medical devices when the extract is compatible with the assay system and when results are interpreted within a weight-of-evidence risk assessment, complemented by toxicological evaluation of extractable compounds per ISO 10993-17 and ISO 10993-18.

Interpretation and Reporting

A compliant test report details sample identification, extraction parameters, test system justification, dose levels, individual animal or cell culture data, control validity, and a clear positive or negative conclusion with grading. Where a positive result is obtained, a risk-benefit analysis considering the margin of safety, patient population, and exposure conditions determines the acceptability of the device or the need for material reformulation.

Applications

ISO 10993 sensitization test data support a broad range of regulatory and quality objectives across the medical device industry:

• Regulatory submissions to the US FDA, including 510(k), De Novo, and PMA applications, where sensitization data are a baseline biocompatibility expectation
• CE marking under the European Medical Device Regulation (MDR 2017/745), integrated into the biological evaluation plan and report per ISO 10993-1
• NMPA registration in China under the harmonized national standard GB/T 16886.10, which mirrors ISO 10993-10 requirements
• Submissions to Health Canada, Japan PMDA, and other national authorities with ICH- and IMDRF-aligned expectations
• Design control activities, including new material selection, supplier qualification, and evaluation of manufacturing or sterilization process changes
• Patient safety surveillance and root cause investigation of adverse event reports involving suspected allergic reactions
• Scientific and ethical compliance with animal welfare directives, such as EU Directive 2010/63, by progressively adopting non-animal strategies

FAQ

When is sensitization testing required for a medical device?

Sensitization testing is expected for any device contacting the patient for more than 24 hours, and for shorter-contact devices whenever chemical characterization or material history indicates sensitizing leachables. Implantable and mucosal-contacting devices almost always require this endpoint under ISO 10993-1 categorization.

Which test method should be selected: GPMT, Buehler, LLNA, or in vitro assays?

Method selection depends on the sample form, clinical exposure route, regulatory target market, and animal welfare policy. The GPMT offers maximum sensitivity for extracts of implantable devices, the Buehler test suits topical exposure, the LLNA provides reduced animal use, and in vitro assays aligned with OECD TG 442 and 497 are increasingly accepted when justified within a documented IATA strategy.

Can non-animal methods fully replace guinea pig studies for regulatory submissions?

Many regulators, including the FDA in recent guidance, accept defined in vitro approaches when assay applicability domains cover the extract chemistry and the overall weight of evidence is strong. However, because device extracts are complex mixtures with solubility constraints, some reviewers may still request confirmatory in vivo testing, so early engagement with the testing laboratory and regulatory strategy is recommended.

Why are both polar and non-polar extraction vehicles used?

Medical devices release both water-soluble and lipid-soluble chemicals. Testing extracts from two vehicles with different polarities ensures that sensitizing leachables across the full polarity range are captured, as required by ISO 10993-12.

What sample quantity and project timeline should be planned for?

Typical programs require several grams or several hundred square centimeters of representative finished material, plus additional units for extraction validation. In vivo guinea pig studies generally require 8 to 10 weeks including acclimation, in-life phases, and reporting, while in vitro panels can often be completed within 4 to 6 weeks.

How are false positive results avoided?

Irritant responses unrelated to immunological sensitization are controlled through concurrent negative controls, pH and osmolality verification of extracts, appropriate occlusion times, and, where needed, follow-up testing such as re-challenge or complementary in vitro assays to confirm the allergenic mechanism.